Reasons To Invest
You can help change the way we diagnose and treat cancer.
We are ready to launch commercially now to help breast and ovarian cancer patients navigate their treatment options when they don't respond or recur after standard of care.
In the journey from idea to clinical validation, we have raised $6.5 million in grants and generated $4.5 million in revenue. Now, our technology and processes are ready to scale.
The crowdfunding platform StartEngine has reviewed our company according to its strict due diligence requirements and given us a place on the platform. It accepts less than 5% of the companies that approach it (less than Y Combinator).
1. We can save lives now
Saving cancer patients' lives NOW repurposing FDA-approved drugs by analyzing patient’s unique RNA profiles. Validated in breast and ovarian cancer with close to 100% diagnostic yield and high concordance with other single biomarker tests. Broad patent has been filed, and regulatory approvals are in place (CLIA) to launch into the $3B women’s cancer market.
2. Commercial Traction
We are commercial stage, and close to positive cash flow. This has been achieved through grants of $6.5M, $1.7M in seed funding, and lifetime revenue of $4.5M. We plan to use the funds to expand sales. There is a payor code reimbursing us $3,000 per OneRNA® test, and our margins are healthy. A potential $3M NCI contract is under consideration.
3. Strong Partnerships
We have a long-standing partnership with Rutgers and the US National Cancer Institute. We have discussions with most of the large oncology-focused hospitals in the USA. We automated lead generation processes for deals with pharma companies to design and de-risk clinical studies and develop companion diagnostics OneRNA® algorithms (AI). Finally, we are advancing methods to rapidly translate RNA code to RNA Therapeutics, which interests several RNA Therapeutics companies and other pharma companies.
